Badges [ 2 ] [-]
Memberships [ 1 ] [+]
Ideas Contributed [ 2 ] [+]
We study cancer in narrow cohorts, excluding comorbidities. By doing so we miss critical info that can lead to earlier identification/treatment. While we must stratify samples, we can do so and include comorbidities that lead to disease pathways.
If data collection is restricted to the US, we may mischaracterize some familial cases as sporadic. We need to include Family History in the NIH/FDA Clinical Trial protocol template (sec.7.1.1) and provide global access to registries/biobanks.